CJC-1295 isn't found on pharmacy shelves in Acsád or virtually any local market — it's a research compound supplied via a dedicated online market. The practical advantage of this online-only market is that serious vendors are judged entirely by their analytical documentation, giving researchers access to better quality signals than local retail ever could. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety documentation. Use this guide to assess sourcing options methodically — the framework here work regardless of your location.
CJC-1295 Mechanisms Explained
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Acsád researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Where to Buy CJC-1295 — A Researcher's Guide
Before looking at individual vendors, understand what genuine quality documentation contains — so you can identify whether a supplier meets the standard. The HPLC analytical chromatogram is the most important document in the COA: it should show a large primary peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be at or above 98%. For Acsád researchers evaluating new suppliers: a modest first purchase to test the product before committing to research quantities is the accepted approach among experienced researchers. Price is an poor proxy for CJC-1295 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so significantly below-market pricing signals compromises.
Order CJC-1295 — ships to Acsád
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and small-scale human observations. Proper handling of CJC-1295 requires careful sterile procedure — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and cold chain maintenance from receipt through use. Quality CJC-1295 sourcing is inseparable from safety — bacterial endotoxin contamination, wrong peptide identity, and degraded material are all safety issues that verified-quality sourcing directly prevents. Researchers running multi-compound protocols with CJC-1295 should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
